The American College of Cardiology (ACC), one of the largest cardiovascular societies in North America along with the American Heart Association (AHA), will hold its annual scientific conference from April 2nd to 4th 2022. Prior to the opening of ACC 22, a press conference was held on March 16th to provide an overview.
ACC 22 - Exploring the Nature of Scientific Conferences in the Post-Corona Era
As previously mentioned in TCROSS NEWS, this year's event will take place in a hybrid on-site and online format. The on-site venue is in Washington, D.C., where the cherry blossoms can be seen at this time of year. Although regulations are still strict in Japan and other countries, limiting the number of on-site participants, some countries have already relaxed their regulations, and the number of on-site conferences is expected to increase in the future.
ACC 22 requires all participants at the venue to have a certificate of proof of COVID-19 vaccination and to wear a mask at all times. A strict inspection system for COVID-19 has also been set up at the venue, since this is the first time the event is being held as a hybrid.
This year's faculty consisted of 2,522 participants, with 419 having been invited from overseas. The number of digital participants was 944, 81% of whom were from the U.S. and 19% from overseas, indicating that many faculty members in the U.S. are still participating remotely. In addition, there were over 200 educational sessions and 8 sessions related to the guidelines.
ACC 22 received 5,307 abstract submissions from 74 countries, and the number of accepted abstracts was more than 3,500. In addition, 112 abstracts were gathered for the Young Investigator Awards, of which 14 will be presented.
The Late-Breaking Clinical Trials and Featured Clinical Research sessions received 117 submissions, of which 56% were from the United States and 44% from overseas, with a total of 39 accepted and divided into 5 Late-Breaking Clinical Trials sessions and 3 Featured Clinical Research sessions.
The following abstracts are scheduled to be presented in the Late-Breaking Clinical Trials and Featured Clinical Research sessions at ACC 22.
Late-Breaking Clinical Trials
FLAVOUR Trial
FFR-Guided PCI Vs. IVUS-Guided PCI for Moderate Coronary Stenosis
CHOCOLATE TOUCH Trial
Chocolate Touch Paclitaxel Coated Balloon for Above Knee Lesions
GIPS-IV Trial
Protection of Cardiac Function by Sodium Thiosulfate After ST-Elevation MI
GHATI Trial
International 2-Year Results for the Management of Patients with ST-Elevation MI
BIO GUARD-MI Trial
Clinical Benefits of Arrhythmia Monitoring After MI
TRANSLATE-TIMI 70 Trial
Vupanorsen on Non-HDL Cholesterol Levels in Statin-Treated Patients with High Cholesterol Levels
PACMAN AMI Trial
Effect of Alirocumab on Atherosclerosis Evaluated by Intracoronary Imaging in Patients with AMI
CoreValve US Pivotal Trial, SURTAVI Trial (5-Year Follow-Up)
Timing and Predictors of Hemodynamic Valve Deterioration After TAVR and SAVR
ADAPT-TAVR Trial
Edoxaban vs. DAPT for Valve Thrombus/Cerebral Thromboembolism After TAVR
VALOR-HCM Trial
Efficacy of Mavacamten as an Alternative to Surgical Septal Myectomy or Alcohol Septal Ablation in Patients with Severe Obstructive Hypertrophic Cardiomyopathy
MAVA-LTE Trial, EXPLORER-LTE Cohort
Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
METEORIC-HF Trial
Omecamtiv Mecarbil for Exercise Tolerance in Patients with Chronic HFrEF
IVVE Trial
Efficacy of Influenza Vaccine in Preventing Adverse Vascular Events in Patients with Heart Failure
PROMPT-HF Trial
Guideline-Driven Medication Therapy (GDMT) for Ambulatory Heart Failure Patients
DIAMOND Trial
Patiromer for Management of Hyperkalemia in HFrEF Patients Using RAAS Inhibitors
POISE-3 Trial
Efficacy and Safety of Tranexamic Acid in Patients Undergoing Noncardiac Surgery
Featured Clinical Research
COMPLETE Trial
Effect of Complete Revascularization on Angina-Related Quality of Life in Patients with ST-Elevation MI
FAME 3 Trial
Quality of Life After FFR-Guided Stenting Vs. CABG
PARTITA Trial
Catheter Ablation for Ventricular Tachycardia After Initial Implantable Cardioverter-Defibrillator Shock
Residual Leakage After Left Ear Closure
CANTOS Trial Subanalysis
Effects of Residual Inflammation and Cholesterol Risk in Patients with Atherosclerosis with and without Chronic Kidney Disease.
PACIFIC AF Trial
Safety of the Oral Factor Xa Inhibitor Asundexian + Apixaban in Patients with Atrial Fibrillation
SCORED Trial
Efficacy of Sotagliflozin in Cardiovascular Death, MI, and Stroke
EMPULSE Trial
Impact of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Hospitalized Patients with Acute Heart Failure
Finerenone and Outcome by History of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus
SPYRAL HTN-ON MED Trial (3-Year Results)
Efficacy of Renal Denervation in Patients on Antihypertensive Medications
NACMI Registry
MI Trends in North American COVID-19 Patients
※コンテンツには、国内で未承認、適応外の医療機器、医薬品、または効能・効果/用法・用量の情報を含む場合がありますが、未承認、適応外の使用を推奨するものではありません。
ご注意 当サイト内の全ての記事と動画の転載・転送はご遠慮ください。なお、法律上保護されたコンテンツの無許可の転載、複製、転用等は、当該コンテンツの権利者等から損害賠償請求その他の法的手続を申し立てられ、事案によっては処罰される可能性、また、故意にそれらを受け取った場合も同様の措置を受ける可能性がございます。ご不明な点がございましたら当社までご連絡ください。
おすすめ
